Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1825114rdf:typepubmed:Citationlld:pubmed
pubmed-article:1825114lifeskim:mentionsumls-concept:C0031330lld:lifeskim
pubmed-article:1825114lifeskim:mentionsumls-concept:C0002520lld:lifeskim
pubmed-article:1825114lifeskim:mentionsumls-concept:C0001128lld:lifeskim
pubmed-article:1825114lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:1825114lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:1825114lifeskim:mentionsumls-concept:C0598958lld:lifeskim
pubmed-article:1825114lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:1825114lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:1825114lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:1825114lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:1825114lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:1825114lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:1825114lifeskim:mentionsumls-concept:C0162827lld:lifeskim
pubmed-article:1825114pubmed:issue1lld:pubmed
pubmed-article:1825114pubmed:dateCreated1991-3-12lld:pubmed
pubmed-article:1825114pubmed:abstractTextThe isoxazole amino acid 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propionic acid (AMPA) (1), which is a highly selective agonist at the AMPA subtype of excitatory amino acid (EAA) receptors, has been used as a lead for the development of two novel EAA receptor antagonists. One of the compounds, 2-amino-3-[3-(carboxymethoxy)-5-methylisoxazol-4-yl]propionic acid (AMOA, 7), was synthesized via O-alkylation by ethyl chloroacetate of the amino acid protected AMPA derivative 4. The other compound, 2-amino-3-[2-(3-hydroxy-5-methylisoxazol-4-yl)-methyl-5-methyl-3-+ ++oxoisoxazolin -4-yl]propionic acid (AMNH, 14) was synthesized with use of 4-(chloromethyl)-3-methoxy-5-methylisoxazole (8) as the starting material. The intermediate 4-(chloromethyl)-2-(3-methoxy-5-methylisoxazol-4-yl)methyl-5-me thylisoxazolin- 3-one (11) was converted into the acetamidomalonate (12), which was stepwise deprotected to give 14. Compounds 7 and 14 were stable in aqueous solution at pH values close to physiological pH. Neither 7 nor 14 showed detectable affinities for the receptor, ion channel, or modulatory sites of the N-methyl-D-aspartic acid (NMDA) receptor complex. Quantitative receptor autoradiographic and conventional binding techniques were used to study the affinities of 7 and 14 for non-NMDA receptor sites. Both compounds were inhibitors of the binding of [3H]AMPA (IC50 = 90 and 29 microM, respectively). Compounds 14 and 7 were both very weak inhibitors of the high-affinity binding of radioactive kainic acid [( 3H]KAIN). Compound 14, but not 7, was, however, shown to be an inhibitor of low-affinity [3H]KAIN binding (IC50 = 40 microM) as determined in the presence of 100 mM calcium chloride. In the rat cortical slice preparation, 7 was shown to antagonize excitation induced by 1 with some selectivity, whereas 14 proved to be a rather selective antagonist of KAIN-induced excitation. Both antagonists showed very weak effects on the excitatory effects of NMDA. Compound 7 was a poor antagonist of excitation by quisqualic acid (2), whereas 14 did not affect excitation by this nonselective AMPA receptor agonist. On cat spinal neurones, both 7 and 14 reduced excitations by 1 and KAIN, but, again, the excitatory effects of 2 were much less sensitive. Compound 14 and, in particular, 7 effectively protected rat striatal neurones against the neurotoxic effects of KAIN, whereas the toxic effects of 1 were reduced only by 7. Neither antagonist showed protection against the cell damage caused by intrastriatal injection of the NMDA agonist quinolinic acid.(ABSTRACT TRUNCATED AT 400 WORDS)lld:pubmed
pubmed-article:1825114pubmed:languageenglld:pubmed
pubmed-article:1825114pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1825114pubmed:citationSubsetIMlld:pubmed
pubmed-article:1825114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1825114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1825114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1825114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1825114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1825114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1825114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1825114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1825114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1825114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1825114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1825114pubmed:statusMEDLINElld:pubmed
pubmed-article:1825114pubmed:monthJanlld:pubmed
pubmed-article:1825114pubmed:issn0022-2623lld:pubmed
pubmed-article:1825114pubmed:authorpubmed-author:CurtisD RDRlld:pubmed
pubmed-article:1825114pubmed:authorpubmed-author:Krogsgaard-La...lld:pubmed
pubmed-article:1825114pubmed:authorpubmed-author:DiemerN HNHlld:pubmed
pubmed-article:1825114pubmed:authorpubmed-author:FerkanyJ WJWlld:pubmed
pubmed-article:1825114pubmed:authorpubmed-author:EberlJJlld:pubmed
pubmed-article:1825114pubmed:authorpubmed-author:BruhnTTlld:pubmed
pubmed-article:1825114pubmed:authorpubmed-author:MadsenUUlld:pubmed
pubmed-article:1825114pubmed:authorpubmed-author:JohansenJ SJSlld:pubmed
pubmed-article:1825114pubmed:authorpubmed-author:BeattieD TDTlld:pubmed
pubmed-article:1825114pubmed:authorpubmed-author:NielsenE OEOlld:pubmed
pubmed-article:1825114pubmed:issnTypePrintlld:pubmed
pubmed-article:1825114pubmed:volume34lld:pubmed
pubmed-article:1825114pubmed:ownerNLMlld:pubmed
pubmed-article:1825114pubmed:authorsCompleteYlld:pubmed
pubmed-article:1825114pubmed:pagination123-30lld:pubmed
pubmed-article:1825114pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:meshHeadingpubmed-meshheading:1825114-...lld:pubmed
pubmed-article:1825114pubmed:year1991lld:pubmed
pubmed-article:1825114pubmed:articleTitleNovel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection.lld:pubmed
pubmed-article:1825114pubmed:affiliationDepartment of Organic Chemistry, Royal Danish School of Pharmacy, Copenhagen, Denmark.lld:pubmed
pubmed-article:1825114pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1825114pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1825114pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:1825114pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:1825114lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1825114lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1825114lld:pubmed